| Title |
Nano-Encapsulation of Plitidepsin: In Vivo Pharmacokinetics, Biodistribution, and Efficacy in a Renal Xenograft Tumor Model
|
|---|---|
| Published in |
Pharmaceutical Research, November 2013
|
| DOI | 10.1007/s11095-013-1220-3 |
| Pubmed ID | |
| Authors |
Hugo Oliveira, Julie Thevenot, Elisabeth Garanger, Emmanuel Ibarboure, Pilar Calvo, Pablo Aviles, Maria Jose Guillen, Sébastien Lecommandoux |
| Abstract |
Plitidepsin is an antineoplasic currently in clinical evaluation in a phase III trial in multiple myeloma (ADMYRE). Presently, the hydrophobic drug plitidepsin is formulated using Cremophor®, an adjuvant associated with unwanted hypersensitivity reactions. In search of alternatives, we developed and tested two nanoparticle-based formulations of plitidepsin, aiming to modify/improve drug biodistribution and efficacy. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| France | 1 | 3% |
| Unknown | 36 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 11 | 30% |
| Researcher | 7 | 19% |
| Other | 4 | 11% |
| Student > Doctoral Student | 3 | 8% |
| Student > Master | 3 | 8% |
| Other | 4 | 11% |
| Unknown | 5 | 14% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 8 | 22% |
| Agricultural and Biological Sciences | 7 | 19% |
| Medicine and Dentistry | 6 | 16% |
| Biochemistry, Genetics and Molecular Biology | 4 | 11% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 5% |
| Other | 3 | 8% |
| Unknown | 7 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2013.
All research outputs
#18,355,685
of 22,733,113 outputs
Outputs from Pharmaceutical Research
#2,472
of 2,853 outputs
Outputs of similar age
#231,718
of 306,616 outputs
Outputs of similar age from Pharmaceutical Research
#13
of 19 outputs
Altmetric has tracked 22,733,113 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,853 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.0. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 306,616 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 12th percentile – i.e., 12% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 19 others from the same source and published within six weeks on either side of this one. This one is in the 31st percentile – i.e., 31% of its contemporaries scored the same or lower than it.